Biology:Metirosine
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Demser |
| Other names | Metyrosine (USAN US) |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data |
|
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 3.4–3.7 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C10H13NO3 |
| Molar mass | 195.218 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Metirosine (INN and BAN; α-Methyltyrosine, Metyrosine USAN, AMPT) is an antihypertensive drug. It inhibits the enzyme tyrosine hydroxylase and, therefore, catecholamine synthesis, which, as a consequence, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body.
It is available as a generic medication.[1]
Clinical use
Metirosine has been shown to suppress catecholamine synthesis and alleviate symptoms related to catecholamine excess, including hypertension, headache, tachycardia, constipation, and tremor.[2] Metirosine is primarily used to reduce these symptoms in patients with pheochromocytoma.[3] It is contraindicated for the treatment of essential hypertension.
Metirosine is used as an off-label treatment for DiGeorge syndrome.[4]
Metirosine is used in scientific research to investigate the effects of catecholamine depletion on behavior.[5] There is evidence that catecholamine depletion causes an increase in sleepiness that is more pronounced than sleep deprivation, and that the fatigue lingers after the drug is discontinued. Catecholamine depletion has also been linked to a negative mood, though this is reported less often than sleepiness.[6]
See also
- p-Chlorophenylalanine
References
- ↑ "Metyrosine: FDA-Approved Drugs". https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213734.
- ↑ Naruse, Mitsuhide; Satoh, Fumitoshi; Tanabe, Akiyo; Okamoto, Takahiro; Ichihara, Atsuhiro; Tsuiki, Mika; Katabami, Takuyuki; Nomura, Masatoshi et al. (2018). "Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan". Endocrine Journal 65 (3): 359–371. doi:10.1507/endocrj.EJ17-0276. ISSN 0918-8959. PMID 29353821.
- ↑ "Alpha-methyltyrosine in the management of phaeochromocytoma". Thorax 37 (8): 632–3. August 1982. doi:10.1136/thx.37.8.632. PMID 7179194.
- ↑ "Doctors said the boy was suffering from teenage psychosis. What he really had was a rare genetic condition.". The Washington Post. 30 April 2021. https://www.washingtonpost.com/health/teenage-psychosis-genetic-condition/2021/04/30/65133794-6be5-11eb-9ead-673168d5b874_story.html.
- ↑ O'Leary, OF; Bechtholt, AJ; Crowley, JJ; Hill, TE; Page, ME; Lucki, I (2007). "Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test". Psychopharmacology 192 (3): 357–71. doi:10.1007/s00213-007-0728-9. PMID 17318507.
- ↑ McCann, Una D.; Penetar, David M.; Shaham, Yavin; Thome, David R.; Sing, Helen C.; Thomas, Maria L.; Gillin, J. Christian; Belenky, Gregory (June 1993). "Effects of Catecholamine Depletion on Alertness and Mood in Rested and Sleep Deprived Normal Volunteers". Neuropsychopharmacology 8 (4): 345–356. doi:10.1038/npp.1993.34. ISSN 0893-133X. PMID 8099791.
External links
- "Metyrosine". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/metyrosine.
 |
